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WHILE repeated applications of a carcinogenic hydrocarbon to the skin of the
mouse leads to the local development ofpapillomas and ultimately of carcinomas,
a single application usually induces only the " initiating phase " of carcinogenesis.
Except for the appearance of epidermal hyperplasia at the site, which is hardly
distinguishable from that produced by ordinary irritation, the evidence of a
specific " initiating " effect is demonstrated bythe fact that tumours are elicited in
such pretreated skin by subsequent applications of a " promoting agent " such
as croton oil (Berenblum and Shubik, 1947, 1949). The difference in mechanism
between the two stages is best illustrated by the observation that reversal of the
sequence of the two actions fails to elicit tumours (Berenblum and Haran, 1955a).
The current concept of the two-stage mechanism of carcinogenesis is that the
initiating phase represents an irreversible transformation of a normal cell into a
" dormant tumour cell ", and that the promoting phase arises through a delay in
maturation of these dormant tumour cells until a critical sized colony is reached
(Berenblum, 1954).
Whenusing acarcinogenic hydrocarbonforinitiating actiona single application
is necessary, otherwise the same compound would begin to act also as a promoting
agent. However, theeffect ofurethane onthe skin, even afterlong-repeated appli-
cations, is restricted to initiating action (Graffi, Vlamynch, Hoffman and Schulz,
1953; Salaman and Roe, 1953; Roe and Salaman, 1954; Berenblum and Haran,
1955b).
In contrast to the "incomplete " carcinogenic action on the skin, urethane is
capable ofacting as a" complete " carcinogen on the lung both in mice (Nettleship
and Henshaw, 1943) and rats (Jaffe, 1947), causing the development of adenomas
in that organ. The effect, which is systemic, apparently involves a metabolic
intermediary (Rogers, 1955). Tumours have also been reported to develop in the
liver of rats by the systemic action of urethane (Jaffe, 1947).
The possibility that a metabolic intermediary was also involved in the case of
the initiating action on the skin by urethane, called for exploration. As a first
step, experiments were un'dertaken to test whether oral administration ofurethane
would render the skin responsive to the promoting action of topical applications
of croton oil.NECHAMA HARAN AND I. BERENBLUM
METHOD
ThemiceusedintheseexperimentswerefemalesoftheSwiss strain, bredinthese
laboratories by brother-to-sister mating for about 14 generations. They were fed
on Puirina Laboratory Chow and water ad libitum, and kept in an air-conditioned
room at 21-23° C.
For the testing of systemic initiating action, 0-3 ml. of a 5 per cent aqueous
solution of urethane was administered orally, by a polyethylene stomach tube,
constituting 15 mg. per dose. Promoting action was by the standard procedure
of twice-weekly applications of 5 per cent croton oil in medicinal liquid paraffin,
to an area of skin of about 2 x 11 cm., in the region ofthe shoulder blades. The
applications were made with a glass rod, after prior clipping of the hair with
scissors. The resulting tumours were charted at their first appearance, and
fortnightly thereafter. Papillomas that regressed within two weeks of their
appearance were not listed in the final records.
RESULTS
In the first experiment (Group I, Table I), the initiating and promoting actions
were given concurrently for 10 weeks (i.e. 10 weekly feedings of urethane and 20
twice-weekly applications of croton oil), after which the croton oil treatmentwas
continued for another 8 weeks. Not only did all the survivors develop tumours at
the site ofthe croton oil applications, but the number of tumours averaged 12 per
mouse (not counting those that had regressed). A photograph ofone mouse ofthis
series is showninFig. 1, inwhich 30papillomas developed atthe site ofapplication.
Since this experiment was complicated bythe concurrent action ofthe urethane-
and the croton oil for the first 10 weeks (representing a test for cocarcinogenic
rather than for initiating action), a second experiment was carried out, under
identical conditions, except that the 36 twice-weekly applications of croton oil
were begun 14 days after completion of the urethane treatment. In this
experiment (Group II, Table I), 18 out of 22 survivors developed papillomas
at the site of croton oil treatment, and the average number of tumours was
2 per mouse.
In a third experiment (Group III, Table I), a single feeding of urethane was
followed, after 2 days, by 36 twice-weekly applications of croton oil to the skin.
The tumour yield was similar to that of Group II, which received 10 feedings of
urethane priortothecrotonoiltreatment. Theresultswere: 27 out of31 survivors,
with an average tumour yield of 2-4 per mouse.
In one control series (Group IV, Table I), 36twice-weekly applications ofcroton
oil were given without any urethane feeding beforehand. Two out of 30 survivors
developed papillomas, the average tumour yield being 0'06 per mouse.
In a second control series (Group V, Table I), urethane was fed for 45 weeks,
once weekly, without eliciting any skin papillomas (though lung adenomas were
found at autopsy in large numbers, as was to be expected).
EXPLANATION OF PLATE.
FIG. 1.-Swiss female mouse receiving 10 feedings of urethane concurrently with 20 topical
applications ofcroton oil, followed by 16 applications of croton oil alone. Thirty papillomas
are present at the site of applications.
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TABLE I.-Production ofSkin Tumours in Mice by OralAdministration of Urethane
Combined with, or Followed by, Topical Applications of Croton Oil.
Average
Mice number Average
Number bearing oftumours latent
of Primary Secondary papillomas/ per period*
Group. mice. treatment. treatment. survivors. animal. (weeks).
30 {Urethane x 10 Croton oil x 16 . 23/23 . 12.0 . 10
II . 25 .Urethane x 10 .,,,, x 36 . 18/22 . 2*0 . 8
III. 33 . ,, x . ,,,, x 36 . 27/31 . 2*4 . 9




V . 37 .Urethane x 45. . 0/37 * 0
Urethane: 0- 3 ml. of 5 per cent aqueous solution, once weekly by stomach tube.
Croton oil: 5 per cent solution in liquid paraffin, applied twice weekly to skin of back.
* Average latent period calculated from commencement of secondary treatment.
DISCUSSION
The results reported here represent the third example of the induction of the
initiating phase of skin carcinogenesis by the systemic route:
The first example was that of Ritchie and Saffiotti (1955) who showed that
orally administered AAF (2-acetylaminofluorene) rendered the skin responsive to
the promoting action ofcroton oil. The unusual feature ofthis observation is that,
when applied topically, this compoundfails to act as aninitiating agent forthe skin
(Price, 1947). The mostlikelyexplanationofthisisthat ametabolicintermediaryis.
involved in the action, and that this does not readily occur percutaneously.
The second example of systemic initiating action for skin was by Graffi,
Scharsach and Heyer (1955) who obtained the effect using DMBA (9: 10-dimethyl-
1 : 2-benzanthracene) administered intravenously, intraperitoneally, or orally,
followed by topical applications of croton oil to the skin. (Unaware of thelatter
publication, we carried out a similar experiment, administering DMBA by stomach
tube in the form of a single dose of 3 mg. in polyethylene glycol-400. All the 26
survivors developed tumours at the site ofsubsequent croton oil applications, with
an average of 7 tumours per animal. The average latent period was 10 weeks fronm
the commencement of the croton oil treatment.) These results are somewhat
different from those obtained with AAF in that DMBA is a potent initiator for the
skin when applied locally (and, of course, also a potent locally-acting carcinogen
when applied repeatedly).
The present results with urethane are, in a sense, different from both those
of AAF and DMBA. Urethane resembles DMBA rather than AAF in displaying
initiating action when applied locally; yet it is non-carcinogenic for skin when
actingalone. Itresembles AAF in one important respect, however, inthatitsaction
on the skin, whether applied locally or reaching the tissue systemically, is devoid
of any indication of epidermal hyperplasia or of any other histological evidence
of cell stimulation or damage.
This provides the most convincing evidence so far obtained against the notion
that epidermal hyperplasia is an essential requirement in the initial phase of
carcinogenesis. The belief in a " preneoplastic hyperplasia " has led to the hypo-60 NECHAMA HARAN AND I. BERENBLUM
thesis ofa " field effect " in the origin ofepidermal carcinogenesis (Willis, 1948)-a
concept at variance with the " focal origin ofa tumour " implicit in the two-stage
mechanism of carcinogenesis. The present results with urethane favour the focal
origin of dormant tumour cells rather than the diffuse field effect hypothesis.
The present results with urethane also have a bearing on the somatic cell
mutation hypothesis of cancer. It has been shown (Bryan, Skipper and White,
1949) that more than 95 per cent of urethane, injected into mice, are rapidly
eliminated from the body, and that the remainder (as urethane or metabolite) is
evenly distributed through the tissues of the body. Consequently, only a minute
fraction ofthe 15 mg. ofurethane, administered orally in the present experiments,
could have found its way to the small area of skin in which evidence ofinitiating
action was demonstrated. If one accepts, furthermore, that any " neoplastic
mutation " could only represent a small fraction of all mutations produced one
wouldhave to assume anunbelievably high mutationrateto explain carcinogenesis
(or the initiating phase of carcinogenesis) on the basis of a somatic mutation.
Some reference should be made, in conclusion, to the similarity in tumour
yield when a single dose and 10 weekly doses, respectively, were given prior to
croton oil applications. The results are reminiscent of those obtained by Shubik
and Ritchie (1953) following one, two, or three applications ofDMBA to the skin,
followed by croton oil applications. They failed to obtain a progressive increase
in tumour yield, in contrast to the earlier results ofBerenblum and Shubik (1949)
that increases in the concentration of the initiating agent did yield corresponding
increases in the number oftumours produced. No explanation ofthis discrepancy
is available, nor of the fact that when the 10 feedings of urethane are given con-
currently with croton oil treatment the tumour yield was strikingly greater.
SUMMARY
Urethane (ethyl carbamate), administered orally, is an effective initiating
agent for the skin in mice, as manifested by the development of papillomas at
the site of concurrent or subsequent croton oil applications to the skin.
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